

Product Data Sheet

Ir-CA


Cat. No.: HY-162344
CAS No.: 2870682-93-0

Molecular Weight: 974.95

Target: Apoptosis; Autophagy
Pathway: Apoptosis; Autophagy

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.



BIOLOGICAL ACTIVITY

Description	Ir-CA is an antitumor agent. Ir-CA can accumulate in mitochondria and induces mitochondria dysfunction. Ir-CA induces apoptosis and autophagy. Ir-CA initiates mitophagy and cell cycle arrest to kill Cisplatin (HY-17394)-resistant A549R cells. Ir-CA can effectively inhibit metastasis by inhibiting MMP-2/MMP-9 ^[1] .
In Vitro	Ir-CA shows cytotoxicity against A549, A549R, HLF, BEAS-2B, MCF-7, 4T1 cells with IC $_{50}$ s of 4.4, 4.5, 6.6, 2.3, 2.6, 5.7 μ M respectively ^[1] . Ir-CA is quickly absorbed by the A549R cells (indicated by the red fluorescence after 1 h of incubation) ^[1] . Ir-CA (10 μ M, 2 h) can accumulate in the mitochondria of living A549 and A549R cells (Co-staining experiments of Ir-CA with Mito-Tracker) ^[1] . Ir-CA (10 μ M, 24 h) damages mitochondrial morphology and the mitochondrial function in A549R cells, and induces ROS production ^[1] . Ir-CA (10 μ M, 24 h) induces cell apoptosis in A549R cells via a nonapoptotic/necrotic pathway, and also increases conversion from LC3-I to LC3-II, suggesting the autophagy ^[1] . Ir-CA (2.5 μ M, 24 h) resensitizes the A549R cells to Cisplatin (HY-17394) ^[1] . Ir-CA (5 μ M, 24 h) inhibitS the metastasis of A549R cells via down-regulation of MMPs ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Ir-CA (5 mg/kg, i.p., once every other day for 8 d) inhibits pulmonary metastasis of A549 cells in metastasis mice models (via injection of the A549 cells from the tail vein) ^[1] . Ir-CA (5 mg/kg, i.p., once every other day for 14 d) inhibits tumor growth in A549 tumor-bearing Balb/c nude mice ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Yang J, et al. Consolidating Organometallic Complex Ir-CA Empowers Mitochondria-Directed Chemotherapy against Resistant Cancer via Stemness and Metastasis Inhibition. Inorg Chem. 2024 Mar 7.

 $\label{lem:caution:Product} \textbf{Caution: Product has not been fully validated for medical applications. For research use only.}$

Tel: 609-228-6898 Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com